CoMeD
Coalition for Mercury-Free Drugs
33A Hoffman Avenue, Lake Hiawatha, NJ 07034-1922

October 21, 2006

Document List for 21 CFR § 10.35 Submission to FDA Public Docket 2004P-0349

Petition for Stay of Decision – Decision Letter Failed To Address Petition Issues[1]

1. **Petition for Stay of Action – cover, petition, and supporting review of FDA ''SEP 26 2006'' letter to CoMeD**. [130 pages in total.]
2. **Appendix A – Review of Fombonne et al. (2006)**. [45 pages in total.]
3. **Appendix B –Review_of_Oct. 2006 FDA_Consumer_magazine's 'Influenza: Vaccination Still Best Protection**.' [25 pages in total.]
4. **Appendix C – MSDS Documents**. [7 pages in total.]
5. **Referenced documents not in petition and/or not referenced by FDA in their ''SEP 26 2006'' ''decision'' letter to CoMeD date-stamped 'SEP 26 2006'**

5.1 "**Ref. 12**": Amin-Zaki L, Majeed MA, Greenwood MR, Elhassani SB, Clarkson TW, Doherty RA. Methylmercury poisoning in the Iraqi suckling infant: a longitudinal study over five years. ***J Appl Toxicol*** 1981; **1**: 210-214.

5.2 "**Ref. 18**": Parran et al. Effects of Thimerosal on NGF signal transduction and cell death in neuroblastoma cells. ***Tox Sci*** 2005; **86**(1): 130-140.

5.3 "**Ref. 20**": Geier DA, King PG, Geier MR. Influenza Vaccine: Review of effectiveness of the U.S. immunization program, and policy considerations. ***J Am Phys Surg*** 2006; **11**(3): 69-74 and the supporting studies referenced therein.

5.4 "**Ref. 22**": Ayoub DM, Yazbak FE. Influenza vaccination during pregnancy: A critical assessment of the recommendations of the Advisory Committee on Immunization Practices (ACIP). ***J Am Phys Surg*** 2006; **11**(1): 41-47.

5.5 "**Ref. 24**": Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. ***Lancet*** 2005; **365**: 773-780.

5.6 "**Ref. 26**": Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. ***Environ Health Perspect***. 2005 April 21; **113**(4). 36-page draft "pdf" file.

5.7 "**Ref. 27**" Sugita M. The biological half-time of heavy metals. The existence of a third ''slowest'' component. ***Int Arch Occup Environ Health*** 1978; **41**(1): 25–40.

5.8 "**Ref. 29**" Stetler HC, Garbe PL, Dwyer DM, Richard R. Facklam RR, Orenstein WA, West GR, Dudley KJ, B. Bloch AB, Outbreaks of group A streptococcal abscesses following diphtheria tetanus toxoid-pertussis vaccination. ***Pediatrics*** 1985; **75**(2): 299-303.

5.9 "**Ref. 34**" Hekkens, F. E. An., Polak-Vogelzang, A. A., and Kreeftenberg, J. G. 1983. The antimicrobial effectiveness of some preservatives in inactivated human vaccines. ***J Biol Stand*** 1983; **9**:277-285.

5.10 "**Ref 35**" Lowe I, Southern J. The antimicrobial activity of phenoxyethanol in vaccines. ***Lett Appl Microbiol*** 1994; **18**: 115-116.

5.11 "**Ref. 39**" Maeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months. ***Pediatr Int*** 2004; **46**: 122-125.

5.12 "**Ref. 40**" Al-Saleh I, El-Doush I, Shinwari N, Al-Baradei R. Does low mercury containing skin-lightening cream (Fair & Lovely) affect the kidney, liver, and brain of female mice? ***Cutaneous & Ocular Tox*** 2005; **24**: 11-29.

5.13 "**Ref. 47**" Gosselin NH, Burnet RC, Carrier G, Bouchard M, Feeley M. Reconstruction of methylmercury intakes in indigenous populations from biomarker data. ***J Expo Anal Environ Epedemiol***. 29 June 2005; **E-pub** (www.nature.com/jea): 1-11

5.14 "**Ref. 55**" Geier DA, Geier MR. Early downward trends in neurodevelopmental disorders following removal of Thimerosal-containing vaccines. ***J Am Phys Surg***. 2006 Spring; **11**(1): 8-12.

5.15 "**Ref. 56**" Geier DA, Geier MR. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines. ***Med Sci Monit***. 2006 May 29; **12**(6): CR231-CR239 [Epub ahead of print].

5.16 "**Ref. 57**" Geier DA, Geier MR. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. ***Neuro Endocrinol Lett***. 2006 Aug 30; **27**(4), in press. [Epub ahead of print].

5.17 "**Ref. 59**" Bingham M, Copes R. Thimerosal in vaccines Balancing the risks of adverse effects with the risk of vaccine-preventable disease. ***Drug Safety*** 2005; **28**(2): 89-101.

5.18 "**Ref. 60**" Waly M, Olteanu H, Banerjee R, Choi S-W, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky V-A, Deth RC, **IMMEDIATE COMMUNICATION**, Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. ***Molecular Psychiatry*** 2004 January 27: 1-13.

[1] **Re:** Public Docket: 2004P-0349/PDN1